Alexion to present seven abstracts, including four oral presentations, from its leading rare neurology portfolio at EAN 2025: Cambridge, UK Monday, June 23, 2025, 13:00 Hrs [IST] ...

Now that Ultomiris has matched the indications of its predecessor Soliris, AstraZeneca is eyeing new avenues for the C5 drug ...

For the second time in nine months, a Delaware judge has sided (PDF) with Syntimmune shareholders over AstraZeneca, granting a $181 million award. The decision comes on top of a $130 million verdict ...

Alexion has routinely featured among lists of top biopharma takeover prospects in the last couple of years, and that was a good call – AstraZeneca has just swooped in with $39 billion cash-and ...

Zanubrutinib shows superior progression-free survival in chronic lymphocytic leukemia compared with acalabrutinib plus ...

AstraZeneca (AZ) has announced promising results from a late-stage study of its C5 complement inhibitor Ultomiris ...

"We are honored to welcome Dr. Ekuta to our Life Sciences Strategic Advisory Board," said Girish Pashilkar, CEO of BP Logix. ...

Baker Brothers’ Q1 2025 portfolio reveals biotech investment trends. See more on their top holdings, stake changes, and ...

Bekkali serves as senior vice president and head of Europe and Canada and International Regions at Alexion, AstraZeneca Rare Disease. On May 24, the World Health Assembly, the governing body of ...

Last year, AstraZeneca reported that a new drug to treat Wilson disease developed by its Alexion rare diseases unit had hit the mark in a phase 3 trial, setting it on course for regulatory filings.

Biologics revolutionize generalized myasthenia gravis care with fast-acting, patient-friendly therapies and a robust global pipeline redefining outcomes. The gMG treatment era is shifting rapidly-from ...